ADVANCED BREAST CANCER

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a certain type of advanced breast cancer (ER+/HER2-). The trial includes 57 participants whose cancer did not respond well to initial treatment. …

This study tests a combination of two drugs (alpelisib and fulvestrant) in 24 Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that worsened after prior hormone therapy. The goal is to see if the combination…

This study tests whether combining two drugs, sacituzumab govitecan and bevacizumab, can help control metastatic triple-negative breast cancer that has not responded to earlier treatments. About 60 adults in China will receive the combination as a second or later line of therapy.…

This study tests a new combination of drugs (alpelisib plus trastuzumab, with or without fulvestrant) against standard chemotherapy for people with a specific type of advanced breast cancer (HER2+, PIK3CA-mutated). The goal is to see if the new combo can delay cancer growth or im…

This phase 3 study compares a new drug, ARV-471, to the standard treatment fulvestrant in people with a common type of advanced breast cancer (ER+/HER2-) that has worsened after prior hormone therapy. About 624 adults whose cancer has spread or cannot be removed will be randomly …

This study tests a combination of two drugs, Debio 0123 and sacituzumab govitecan, in people with advanced breast cancer that has not responded to previous treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 participants will tak…

This early-stage trial tests a radioactive drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug targets cancer cells that have a protein called SSTR on their surface. The study aims to find t…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose…

This study is for people with advanced HER2+ breast cancer whose cancer has spread to the brain but is stable elsewhere. Participants will continue their current treatment and add the drug tucatinib to see if it can delay or prevent new brain tumors. The goal is to improve contro…

This study looks at whether a specially trained support coordinator can help women with advanced or high-risk breast cancer feel heard and understood. About 28 women will take part in this pilot program at the National Cancer Centre Singapore. The coordinator will provide emotion…

This study looks at 25 women with advanced breast cancer to understand why the drug Palbociclib stops working over time. Researchers collect blood and breath samples before and after the cancer progresses. The goal is to find molecular changes that signal resistance, which could …